Delivery Order SPE2DB20D1109-SPE2DB25FN13P

Award Date 11/21/24
Potential Completion Date 11/22/24
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,456.59 delivery order contract is for the supply of Emgality 120 mg/ml medication. It is a firm fixed-price contract with a completion date of February 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is a delivery order issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,754.24 firm fixed price contract is for the supply of Emgality 300 mg (100 mg x 3 syringes) medication. This order is a part of Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA, which provides a wide range of pharmaceutical and medical products to support military...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,593.50 Firm Fixed Price Delivery Order covers the supply of Emgality 120 mg/mL injectable medication, with a period of performance through December 4, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,729.00 firm fixed-price delivery order is for the medication Emgality 120 mg/ml pen injector, and has a completion date of November 20, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract, valued at up to $3,212.48, is for the delivery of Emgality 120 mg/ml injectable medication. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
This federal contract award, valued at $3,208.62, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the pharmaceutical product Emgality 120 mg/ml, with a period of performance through March 14, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award is for the delivery of Emgality 300 mg (100 mg x 3 syringes) to the Defense Logistics Agency (DLA). The contract, valued at $2,320.50, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a vehicle for...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $4,860.38, is a delivery order for the pharmaceutical product Emgality 300 mg (100 mg x 3 syr) ml. The contract has a firm fixed price and an ultimate completion date of December 16, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,486.09 firm-fixed-price delivery order is for the supply of Emgality 120 mg/ml injection medication. The contract has an ultimate completion date of September 25, 2023 and was awarded on September 22, 2023. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,969.14 firm-fixed-price delivery order covers the supply of Emgality 120 mg/ml pen to DLA. The contract has an ultimate completion date of November 29, 2023 and was awarded on November 28, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB25FN13P
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,320.50 firm-fixed-price delivery order covers the supply of Emgality 300 mg (100 mg x 3 syringes) medication, with a completion date of November 22, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. This award demonstrates Amerisourcebergen's role as a key vendor for federal healthcare programs, particularly within the Department of Defense's military treatment facilities and veterans' healthcare systems.

Generated 2/20/25, 9:08 AM